Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus NURTEC ODT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus NURTEC ODT.
AIMOVIG vs NURTEC ODT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
CGRP receptor antagonist; blocks binding of calcitonin gene-related peptide to its receptor, inhibiting vasodilation and neurogenic inflammation in trigeminovascular system.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
75 mg orally once daily as needed, not to exceed 75 mg in 24 hours.
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life of approximately 11 hours, supporting twice-daily dosing for migraine prevention.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Roughly 75% of dose excreted in feces (as unchanged drug and metabolites), 24% in urine (mostly metabolites, <1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist